Related references
Note: Only part of the references are listed.Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
The nuclear export protein XPO1-from biology to targeted therapy
Asfar S. Azmi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Jingsong Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
Zhi-Chuan Zhu et al.
CELL DEATH & DISEASE (2019)
PARP Inhibitors in Prostate Cancer-the Preclinical Rationale and Current Clinical Development
Verneri Virtanen et al.
GENES (2019)
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Qin Feng et al.
FRONTIERS IN ONCOLOGY (2019)
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
Jon H. Chung et al.
JCO PRECISION ONCOLOGY (2019)
Karyopherins in cancer
Tolga Cagatay et al.
CURRENT OPINION IN CELL BIOLOGY (2018)
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
E. David Crawford et al.
JOURNAL OF UROLOGY (2018)
Molecular and cellular mechanisms of castration resistant prostate cancer (Review)
Yiqiao Huang et al.
ONCOLOGY LETTERS (2018)
Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
Trinayan Kashyap et al.
Oncotarget (2018)
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
Amro Aboukameel et al.
Oncotarget (2018)
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
J. Etchin et al.
LEUKEMIA (2017)
Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance
Yang Zhan et al.
MOLECULAR CANCER RESEARCH (2017)
Androgen receptor inhibitor-induced BRCAness and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Likun Li et al.
SCIENCE SIGNALING (2017)
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
Giovanni Luca Gravina et al.
ONCOTARGET (2017)
Androgen receptor inhibitor-induced BRCAness and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Likun Li et al.
SCIENCE SIGNALING (2017)
Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1
Tao Qin et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
The molecular mechanism for nuclear transport and its application
Yun Hak Kim et al.
ANATOMY & CELL BIOLOGY (2017)
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
Z. A. Hing et al.
LEUKEMIA (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer
John L. Silberstein et al.
CURRENT UROLOGY REPORTS (2016)
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models
Giovanni Luca Gravina et al.
BMC CANCER (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein
Jo Ishizawa et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass
Chih-Cheng Yang et al.
ONCOTARGET (2015)
FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer
Dominic Jones et al.
ONCOTARGET (2015)
The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7
Jacqueline Stockley et al.
SCIENTIFIC REPORTS (2015)
Growth factor and signaling pathways and their relevance to prostate cancer therapeutics
Jocelyn L. Wozney et al.
CANCER AND METASTASIS REVIEWS (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer
Janet Mendonca et al.
ONCOTARGET (2014)
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
T. Karantanos et al.
ONCOGENE (2013)
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
William R. Polkinghorn et al.
CANCER DISCOVERY (2013)
Nuclear export of proteins and drug resistance in cancer
Joel G. Turner et al.
BIOCHEMICAL PHARMACOLOGY (2012)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease
Michael J. Donovan et al.
BJU INTERNATIONAL (2010)
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
Victoria J. Weston et al.
BLOOD (2010)
Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality
Preet K. Dhillon et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo
Sarah C. Mutka et al.
CANCER RESEARCH (2009)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Qianben Wang et al.
CELL (2009)
Pleiotropic Functional Properties of Androgen Receptor Mutants in Prostate Cancer
Jean-Pierre Bergerat et al.
HUMAN MUTATION (2009)
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
Kanishka Sircar et al.
JOURNAL OF PATHOLOGY (2009)
Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression
S. Azoulay et al.
JOURNAL OF PATHOLOGY (2008)
Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase
Anna E. O. Fisher et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression
Charles J. Ryan et al.
UROLOGY (2006)
Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion
CH Cheng et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Signal-dependent regulation of splicing via phosphorylation of Sam68
N Matter et al.
NATURE (2002)
Share Paper
